HZNP Stock Overview
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
Horizon Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$88.42|
|52 Week High||US$120.54|
|52 Week Low||US$82.51|
|1 Month Change||-17.13%|
|3 Month Change||-4.74%|
|1 Year Change||-5.64%|
|3 Year Change||263.42%|
|5 Year Change||784.20%|
|Change since IPO||866.34%|
Recent News & Updates
Horizon Therapeutics (NASDAQ:HZNP) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Horizon: For Those Who Dare
Horizon's inflammation segment is on fire in a not good way. The biopharmaceutical firm's orphan therapies segment presents another, far more interesting opportunity. The company is performing well in a perilous market environment.
|HZNP||US Biotechs||US Market|
Return vs Industry: HZNP exceeded the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: HZNP exceeded the US Market which returned -13.2% over the past year.
|HZNP Average Weekly Movement||5.4%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: HZNP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HZNP's weekly volatility (5%) has been stable over the past year.
About the Company
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.
Horizon Therapeutics Fundamentals Summary
|HZNP fundamental statistics|
Is HZNP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HZNP income statement (TTM)|
|Cost of Revenue||US$855.34m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||3.75|
|Net Profit Margin||22.87%|
How did HZNP perform over the long term?See historical performance and comparison
Is Horizon Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HZNP ($88.42) is trading below our estimate of fair value ($278.07)
Significantly Below Fair Value: HZNP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HZNP is poor value based on its Price-To-Earnings Ratio (23.6x) compared to the US Biotechs industry average (15.7x).
PE vs Market: HZNP is poor value based on its Price-To-Earnings Ratio (23.6x) compared to the US market (14.9x).
Price to Earnings Growth Ratio
PEG Ratio: HZNP is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: HZNP is overvalued based on its Price-To-Book Ratio (4.2x) compared to the US Biotechs industry average (1.4x).
How is Horizon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HZNP's forecast earnings growth (24.8% per year) is above the savings rate (1.9%).
Earnings vs Market: HZNP's earnings (24.8% per year) are forecast to grow faster than the US market (12.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HZNP's revenue (11.6% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: HZNP's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HZNP's Return on Equity is forecast to be high in 3 years time (22.6%)
How has Horizon Therapeutics performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HZNP has high quality earnings.
Growing Profit Margin: HZNP's current net profit margins (22.9%) are higher than last year (12.8%).
Past Earnings Growth Analysis
Earnings Trend: HZNP has become profitable over the past 5 years, growing earnings by 64% per year.
Accelerating Growth: HZNP's earnings growth over the past year (207.9%) exceeds its 5-year average (64% per year).
Earnings vs Industry: HZNP earnings growth over the past year (207.9%) exceeded the Biotechs industry 96.9%.
Return on Equity
High ROE: HZNP's Return on Equity (17.9%) is considered low.
How is Horizon Therapeutics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: HZNP's short term assets ($2.9B) exceed its short term liabilities ($825.2M).
Long Term Liabilities: HZNP's short term assets ($2.9B) do not cover its long term liabilities ($3.1B).
Debt to Equity History and Analysis
Debt Level: HZNP's net debt to equity ratio (19.2%) is considered satisfactory.
Reducing Debt: HZNP's debt to equity ratio has reduced from 157% to 53.3% over the past 5 years.
Debt Coverage: HZNP's debt is well covered by operating cash flow (48.8%).
Interest Coverage: HZNP's interest payments on its debt are well covered by EBIT (10.7x coverage).
What is Horizon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HZNP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HZNP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HZNP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HZNP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HZNP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Walbert (54 yo)
Mr. Timothy P. Walbert, also known as Tim, had been the Chairman of the Board at Exicure, Inc. since April 2020 until February 4, 2022 and had been its Independent Director since July 22, 2019 until Februa...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD21.35M) is above average for companies of similar size in the US market ($USD13.26M).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
Experienced Management: HZNP's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: HZNP's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HZNP insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Horizon Therapeutics Public Limited Company's employee growth, exchange listings and data sources
- Name: Horizon Therapeutics Public Limited Company
- Ticker: HZNP
- Exchange: NasdaqGS
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$20.326b
- Shares outstanding: 229.88m
- Website: https://www.horizontherapeutics.com
Number of Employees
- Horizon Therapeutics Public Limited Company
- 70 St. Stephen’s Green
- Co. Dublin
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.